HanAll BioPharma Co., Ltd. clinical trials
Acquired by Daewoong Pharmaceutical Co. LTD.
The registry lists 16 studies whose lead sponsor is HanAll BioPharma Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 8, 2026.
Registry sponsor names on this page
- HanAll BioPharma Co., Ltd.16 studies
Something wrong with this grouping? Tell us on the Daewoong Pharmaceutical Co. LTD. page.
Studies
Recruiting first, then most recently updated. Showing 16 of 16. All Daewoong Pharmaceutical Co. LTD. studies →
- Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious PubertyActive, not recruitingNCT06926933Phase 4
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- A Study Assessing the Safety of Oral ATH-399A in Healthy Adult ParticipantsCompletedNCT06088784Phase 1
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic DermatitisCompletedNCT01568489Phase 2
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CCompletedNCT01194037Phase 1/2
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mgCompletedNCT01806311Phase 1
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)CompletedNCT02988362Phase 1
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye DiseaseSuspendedNCT06400589Phase 3
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- A Study to Assess Efficacy of HL036 in Subjects With Dry EyesCompletedNCT03334539Phase 2
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry EyeCompletedNCT05109702Phase 3
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry EyesCompletedNCT03846453Phase 3
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Phase 1 Study for Safety and Tolerability of HL036CompletedNCT02717208Phase 1
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Efficacy and Safety Study of ELIGARD 22.5mg With Prostate CancerCompletedNCT01511874Phase 4
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Efficacy and Safety of HL-040XC in Essential Hypertension and HyperlipidemiaCompletedNCT01541943Phase 3
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Pharmacokinetic Interactions and Safety Study of Telmisartan and ChlorthalidoneCompletedNCT01806363Phase 1
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male SubjectsCompletedNCT01806324Phase 1
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group
- Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male VolunteersCompletedNCT01440686Phase 1
Sponsor listed in the registry: HanAll BioPharma Co., Ltd. · HanAll BioPharma Co., Ltd. — acquired company within the Daewoong Pharmaceutical Co. LTD. group